Tariffs are monies paid on goods coming into or going out of a country, whilst executive orders are directives issued by a head ...

It is a tale of human nature at its best while confronted with human evil at its worst ... Two floors down on the Cantor Fitzgerald floor, trader Jimmy DeBlase was on the phone to his wife ...

Tesla (NASDAQ: TSLA) stock is showing short-term bullish sentiment as investors speculate it could be gearing up for a ...

Cantor Fitzgerald announces it will be expanding it's Bitcoin financing services in the wake of Trump administration changes. Reflecting the United States’ growing embrace of Bitcoin, investment bank ...

Cantor Fitzgerald upgraded Tesla (TSLA, Financials) to Overweight from Neutral, citing a buying opportunity following the recent sell-off, the firm announced after a site visit to Tesla's ...

Since ending in correction territory last week, Wall Street has rebounded, and Cantor Fitzgerald believes this rally could extend through to the end of the month. However, despite the potential ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating.Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory and AI data centers in Austin. The firm moved Tesla (NASDAQ ...

The Irish unit of Cantor Fitzgerald, the US investment group previously run by Donald Trump’s new commerce secretary, has been fined €452,790 by the Central Bank for failing on a number of ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor ...

Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. Get Belite Bio alerts: ...

Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Get Protara Therapeutics alerts: ...